 MIAMI, Sept. 29, 2021 GLOBE NEWSWIRE -- Longeveron Inc. NASDAQ: LGVN Longeveron or Company, a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced preliminary top line results from ongoing biomarker analysis from the Companys Phase 2b trial of Lomecel-B investigational cell therapy in Aging Frailty subjects. 